Doxorubicin Cardiomyopathy

By K. Chatterjee, Jianqing Zhang, N. Honbo, J. Karliner. The Cardiology, 2009

878 citations recorded by the source corpus.

Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.

Subfields: Cardiology and Cardiovascular Medicine, Materials Chemistry

View Paper: https://www.semanticscholar.org/paper/6475749480b33d637059d120bfa95438e7b03b8f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Oktay Tacar
2. P. Sriamornsak
3. C. Dass

Citations in the corpus

• Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems (2013, background): “The severity of these effects and their occurrence depends on the dosage of doxorubicin and the regeneration capacity of the patient’s bone marrow.([51]) By continuously administering doxorubicin into a small vein, problems such as phlebosclerosis (thickening of vein walls) can occur, and if extrava”